These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

781 related items for PubMed ID: 18585634

  • 1. [Management of Ta, T1, and in situ bladder carcinoma: what is new?].
    Irani J.
    Prog Urol; 2008 May; 18 Suppl 5():S94-8. PubMed ID: 18585634
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J, Crego M, Sabaté S, Salvador J, Palou J, Villavicencio H.
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [Abstract] [Full Text] [Related]

  • 4. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
    Herr HW.
    J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
    Yumura Y, Oogo Y, Takase K, Hamano A, Yamashita Y, Noguchi S, Satomi Y.
    Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
    [Abstract] [Full Text] [Related]

  • 7. The role of tumor-free status in repeat resection before intravesical bacillus Calmette-Guerin for high grade Ta, T1 and CIS bladder cancer.
    Guevara A, Salomon L, Allory Y, Ploussard G, de la Taille A, Paul A, Yiou R, Hoznek A, Dahan M, Abbou CC, Vordos D.
    J Urol; 2010 Jun; 183(6):2161-4. PubMed ID: 20399454
    [Abstract] [Full Text] [Related]

  • 8. Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors.
    Alkhateeb SS, Van Rhijn BW, Finelli A, van der Kwast T, Evans A, Hanna S, Vajpeyi R, Fleshner NE, Jewett MA, Zlotta AR.
    J Urol; 2010 Jul; 184(1):81-6. PubMed ID: 20478593
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
    Böhle A, Bock PR.
    Urology; 2004 Apr; 63(4):682-6; discussion 686-7. PubMed ID: 15072879
    [Abstract] [Full Text] [Related]

  • 13. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin.
    Nativ O, Witjes JA, Hendricksen K, Cohen M, Kedar D, Sidi A, Colombo R, Leibovitch I.
    J Urol; 2009 Oct; 182(4):1313-7. PubMed ID: 19683278
    [Abstract] [Full Text] [Related]

  • 14. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.
    Malmström PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, Solsona E, Di Stasi SM, Witjes JA.
    Eur Urol; 2009 Aug; 56(2):247-56. PubMed ID: 19409692
    [Abstract] [Full Text] [Related]

  • 15. [Bacillus of Calmette-Guérin immunotherapy: which protocol?].
    Saint F.
    Prog Urol; 2008 May; 18 Suppl 5():S99-104. PubMed ID: 18585635
    [Abstract] [Full Text] [Related]

  • 16. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
    Fujimoto K, Chihara Y, Kondo H, Hirao Y.
    Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
    [Abstract] [Full Text] [Related]

  • 17. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
    Divrik RT, Yildirim U, Zorlu F, Ozen H.
    J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
    [Abstract] [Full Text] [Related]

  • 18. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E, Fujimoto H, Mizutani Y, Okajima E, Koga H, Hinotsu S, Shinohara N, Oya M, Miki T, Cancer Registration Committee of the Japanese Urological Association.
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [Abstract] [Full Text] [Related]

  • 19. Intravesical instillations with bacillus calmette-guérin for the treatment of carcinoma in situ involving prostatic ducts.
    Palou Redorta J, Schatteman P, Huguet Pérez J, Segarra Tomás J, Rosales Bordes A, Algaba F, Villavicencio Mavrich H.
    Eur Urol; 2006 May; 49(5):834-8; discussion 838. PubMed ID: 16426729
    [Abstract] [Full Text] [Related]

  • 20. Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group.
    Koga H, Ozono S, Tsushima T, Tomita K, Horiguchi Y, Usami M, Hirao Y, Akaza H, Naito S, BCG Tokyo Strain Study Group.
    Int J Urol; 2010 Sep; 17(9):759-66. PubMed ID: 20604814
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.